Marcus Maurer sadly passed away during the submission of this Correspondence. His invaluable contributions to this study research are honoured with recognition in memoriam. Novartis provided both medical writing support and funding for this Correspondence and the PEARL trials.TS, VV, and MP are employees and shareholders of Novartis. AMG-A reports grants from Escient, Noucor, Novartis, Instituto Carlos III–FEDER, and Uriach Pharma; consulting fees from Almirall, Amgen, Blue Print, Celldex, Celltrium, Escient, Faes, Genentech, GSK, Jaspers, Leo Pharma, Mitsubishi Tanabe, Novartis, Noucor, Sanofi–Regeneron, Thermo Fisher Scientific, Septerna, Servier, and Uriach Pharma; payment or honoraria from Almirall, Avene, Genentech, GSK, Leo Pharma, Menarini, MSD, Noucor, Novartis, Sanofi, and Uriach Pharma; and support for attending meetings or travel from Novartis.